These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 30268764

  • 21. ShearWave™ Elastography BE1 multinational breast study: additional SWE™ features support potential to downgrade BI-RADS®-3 lesions.
    Schäfer FK, Hooley RJ, Ohlinger R, Hahne U, Madjar H, Svensson WE, Balu-Maestro C, Juhan V, Athanasiou A, Mundinger A, Order B, Locatelli M, Cosgrove D, Wolf OJ, Henry JP, Moutfi M, Gay JM, Cohen-Bacrie C.
    Ultraschall Med; 2013 Jun; 34(3):254-9. PubMed ID: 23709241
    [Abstract] [Full Text] [Related]

  • 22. Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications.
    Cilotti A, Iacconi C, Marini C, Moretti M, Mazzotta D, Traino C, Naccarato AG, Piagneri V, Giaconi C, Bevilacqua G, Bartolozzi C.
    Radiol Med; 2007 Mar; 112(2):272-86. PubMed ID: 17361370
    [Abstract] [Full Text] [Related]

  • 23. Risk of malignancy in palpable solid breast masses considered probably benign or low suspicion: implications for management.
    Giess CS, Smeglin LZ, Meyer JE, Ritner JA, Birdwell RL.
    J Ultrasound Med; 2012 Dec; 31(12):1943-9. PubMed ID: 23197547
    [Abstract] [Full Text] [Related]

  • 24. Diagnostic performance of initial enhancement analysis using ultra-fast dynamic contrast-enhanced MRI for breast lesions.
    Goto M, Sakai K, Yokota H, Kiba M, Yoshida M, Imai H, Weiland E, Yokota I, Yamada K.
    Eur Radiol; 2019 Mar; 29(3):1164-1174. PubMed ID: 30088064
    [Abstract] [Full Text] [Related]

  • 25. Imaging and Histopathologic Features of BI-RADS 3 Lesions Upgraded during Imaging Surveillance.
    Michaels A, Chung CS, Birdwell RL, Frost EP, Giess CS.
    Breast J; 2017 Jan; 23(1):10-16. PubMed ID: 27612001
    [Abstract] [Full Text] [Related]

  • 26. A pilot study to determine the diagnostic criteria of spiculated masses for BI-RADS MRI category 5: when to perform re-biopsy after discordant pathologic result?
    Onishi N, Kataoka M, Kanao S, Kawai M, Iima M, Ohashi A, Toi M, Togashi K.
    Breast Cancer; 2017 Jan; 24(1):69-78. PubMed ID: 26832858
    [Abstract] [Full Text] [Related]

  • 27. Role of magnetic resonance imaging in probably benign (BI-RADS category 3) microcalcifications of the breast.
    Linda A, Zuiani C, Londero V, Di Gaetano E, Dal Col A, Girometti R, Bazzocchi M.
    Radiol Med; 2014 Jun; 119(6):393-9. PubMed ID: 24297595
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of the applicability of BI-RADS® MRI for the interpretation of contrast-enhanced digital mammography.
    Travieso-Aja MM, Maldonado-Saluzzi D, Naranjo-Santana P, Fernández-Ruiz C, Severino-Rondón W, Rodríguez Rodríguez M, Luzardo OP.
    Radiologia (Engl Ed); 2019 Jun; 61(6):477-488. PubMed ID: 31262509
    [Abstract] [Full Text] [Related]

  • 29. False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study.
    Baltzer PA, Benndorf M, Dietzel M, Gajda M, Runnebaum IB, Kaiser WA.
    AJR Am J Roentgenol; 2010 Jun; 194(6):1658-63. PubMed ID: 20489110
    [Abstract] [Full Text] [Related]

  • 30. The MRI characteristics of non-mass enhancement lesions of the breast: associations with malignancy.
    Aydin H.
    Br J Radiol; 2019 Apr; 92(1096):20180464. PubMed ID: 30673299
    [Abstract] [Full Text] [Related]

  • 31. The additional utility of ultrafast MRI on conventional DCE-MRI in evaluating preoperative MRI of breast cancer patients.
    Lee SJ, Ko KH, Jung HK, Koh JE, Park AY.
    Eur J Radiol; 2020 Mar; 124():108841. PubMed ID: 31981877
    [Abstract] [Full Text] [Related]

  • 32. A Pivotal Study of Optoacoustic Imaging to Diagnose Benign and Malignant Breast Masses: A New Evaluation Tool for Radiologists.
    Neuschler EI, Butler R, Young CA, Barke LD, Bertrand ML, Böhm-Vélez M, Destounis S, Donlan P, Grobmyer SR, Katzen J, Kist KA, Lavin PT, Makariou EV, Parris TM, Schilling KJ, Tucker FL, Dogan BE.
    Radiology; 2018 May; 287(2):398-412. PubMed ID: 29178816
    [Abstract] [Full Text] [Related]

  • 33. Revisiting Nonmass Enhancement in Breast MRI: Analysis of Outcomes and Follow-Up Using the Updated BI-RADS Atlas.
    Chikarmane SA, Michaels AY, Giess CS.
    AJR Am J Roentgenol; 2017 Nov; 209(5):1178-1184. PubMed ID: 28834447
    [Abstract] [Full Text] [Related]

  • 34. Computer-aided classification of BI-RADS category 3 breast lesions.
    Buchbinder SS, Leichter IS, Lederman RB, Novak B, Bamberger PN, Sklair-Levy M, Yarmish G, Fields SI.
    Radiology; 2004 Mar; 230(3):820-3. PubMed ID: 14739315
    [Abstract] [Full Text] [Related]

  • 35. Incidentally detected enhancing lesions found in breast MRI: analysis of apparent diffusion coefficient and T2 signal intensity significantly improves specificity.
    Arponen O, Masarwah A, Sutela A, Taina M, Könönen M, Sironen R, Hakumäki J, Vanninen R, Sudah M.
    Eur Radiol; 2016 Dec; 26(12):4361-4370. PubMed ID: 27114285
    [Abstract] [Full Text] [Related]

  • 36. Rate of malignancy in MRI-detected probably benign (BI-RADS 3) lesions.
    Spick C, Szolar DH, Baltzer PA, Tillich M, Reittner P, Preidler KW, Pinker-Domenig K, Helbich TH.
    AJR Am J Roentgenol; 2014 Mar; 202(3):684-9. PubMed ID: 24555608
    [Abstract] [Full Text] [Related]

  • 37. Probably Benign Breast Nodular Lesions (BI-RADS 3): Correlation between Ultrasound Features and Histologic Findings.
    Pistolese CA, Tosti D, Citraro D, Ricci F, Di Stefano C, Lamacchia F, Ferrari D, Floris R.
    Ultrasound Med Biol; 2019 Jan; 45(1):78-84. PubMed ID: 30340921
    [Abstract] [Full Text] [Related]

  • 38. Adding a Model-free Diffusion MRI Marker to BI-RADS Assessment Improves Specificity for Diagnosing Breast Lesions.
    Goto M, Le Bihan D, Yoshida M, Sakai K, Yamada K.
    Radiology; 2019 Jul; 292(1):84-93. PubMed ID: 31112086
    [No Abstract] [Full Text] [Related]

  • 39. The value of breast MRI for BI-RADS category 4B mammographic microcalcification: based on the 5th edition of BI-RADS.
    Eun NL, Son EJ, Gweon HM, Youk JH, Kim JA.
    Clin Radiol; 2018 Aug; 73(8):750-755. PubMed ID: 29853301
    [Abstract] [Full Text] [Related]

  • 40. The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams.
    Milos RI, Pipan F, Kalovidouri A, Clauser P, Kapetas P, Bernathova M, Helbich TH, Baltzer PAT.
    Eur Radiol; 2020 Nov; 30(11):6052-6061. PubMed ID: 32504098
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.